Trial · NCT03282799
Results by group34
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 34
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Participants That Ovulate During Month 3 | Standard Dose Etonogestrel Implant | 11 | Participants | ||
| Proportion of Participants That Ovulate During Month 3 | Increased Dose Etonogestrel Implant | 0 | Participants | ||
| Proportion of Participants That Ovulate During Month 6 | Standard Dose Etonogestrel Implant | 17 | Participants | ||
| Proportion of Participants That Ovulate During Month 6 | Increased Dose Etonogestrel Implant | 0 | Participants | ||
| Proportion of Participants That Ovulate During Month 12 | Standard Dose Etonogestrel Implant | 19 | Participants | ||
| Proportion of Participants That Ovulate During Month 12 | Increased Dose Etonogestrel Implant | 2 | Participants | ||
| Proportion of Cervical Mucus Scores Greater Than 10 | Standard Dose Etonogestrel Implant | Cervical mucus score greater than 10 | 1 | Cervical mucus samples | |
| Proportion of Cervical Mucus Scores Greater Than 10 | Increased Dose Etonogestrel Implant | Cervical mucus score greater than 10 | 1 | Cervical mucus samples | |
| Proportion of Cervical Mucus Scores Greater Than 10 | Standard Dose Etonogestrel Implant | Cervical mucus score of 10 or less | 248 | Cervical mucus samples | |
| Proportion of Cervical Mucus Scores Greater Than 10 | Increased Dose Etonogestrel Implant | Cervical mucus score of 10 or less | 233 | Cervical mucus samples | |
| Median Efavirenz Concentration at Enrollment | Standard Dose Etonogestrel Implant | 2.26 | Inter-Quartile Range 1.15 to 4.63 | µg/mL | |
| Median Efavirenz Concentration at Enrollment | Increased Dose Etonogestrel Implant | 2.30 | Inter-Quartile Range 1.28 to 3.65 | µg/mL | |
| Median Efavirenz Concentration at Week 4 | Standard Dose Etonogestrel Implant | 2.41 | Inter-Quartile Range 1.47 to 4.26 | µg/mL | |
| Median Efavirenz Concentration at Week 4 | Increased Dose Etonogestrel Implant | 2.23 | Inter-Quartile Range 1.38 to 5.46 | µg/mL | |
| Median Efavirenz Concentration at Week 12 | Standard Dose Etonogestrel Implant | 2.10 | Inter-Quartile Range 1.22 to 3.99 | µg/mL | |
| Median Efavirenz Concentration at Week 12 | Increased Dose Etonogestrel Implant | 1.88 | Inter-Quartile Range 1.35 to 2.87 | µg/mL | |
| Median Efavirenz Concentration at Week 24 | Standard Dose Etonogestrel Implant | 2.26 | Inter-Quartile Range 1.31 to 4.12 | µg/mL | |
| Median Efavirenz Concentration at Week 24 | Increased Dose Etonogestrel Implant | 1.76 | Inter-Quartile Range 1.18 to 3.47 | µg/mL | |
| Median Efavirenz Concentration at Week 36 | Standard Dose Etonogestrel Implant | 1.97 | Inter-Quartile Range 1.18 to 5.27 | µg/mL | |
| Median Efavirenz Concentration at Week 36 | Increased Dose Etonogestrel Implant | 1.87 | Inter-Quartile Range 1.09 to 4.28 | µg/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03282799/results